Core Laboratories Inc. filed its Form 10-Q with the SEC on October 30, 2026, reporting unaudited financial results for the quarterly period ended September 30, 2026.

Key Highlights

  • Total revenue of $132.1 million for Q3 2026, down from $134.5 million in Q3 2025, according to the filing.
  • Net income attributable to Core Laboratories Inc. of $5.444 million for Q3 2026, compared to $14.239 million in the prior-year quarter.
  • Basic and diluted earnings per share of $0.12 for the three months ended September 30, 2026, versus $0.31 basic and $0.30 diluted in Q3 2025.
  • Nine-month total revenue of $378.5 million for the period ended September 30, 2026, compared to $388.3 million for the same period in 2025.
  • Total assets of $593.5 million as of September 30, 2026, up from $584.0 million at December 31, 2025.
  • Long-term debt, net, of $112.4 million as of September 30, 2026, compared to $110.3 million at December 31, 2025.
  • Shares outstanding of 45,823,203 as of October 23, 2026, per the filing cover page.

Core Laboratories Q3 2026 Financial Results: Revenue, Earnings, and Balance Sheet

According to the filing, Core Laboratories Inc. (NYSE:CLB) reported total revenue of $132.077 million for the three months ended September 30, 2026, comprising $96.007 million in services revenue and $36.070 million in product sales. This compares to total revenue of $134.521 million in the same quarter of 2025, when services contributed $101.125 million and product sales $33.396 million. Operating income for Q3 2026 was $12.065 million, down from $20.928 million in Q3 2025, the filing disclosed.

For the nine months ended September 30, 2026, the company reported total revenue of $378.483 million and operating income of $23.103 million, according to the filing. Net income attributable to Core Laboratories Inc. for the nine-month period was $10.611 million, or $0.23 per basic share and $0.23 per diluted share, compared to $24.721 million, or $0.53 per basic share and $0.52 per diluted share, for the nine months ended September 30, 2025. Income tax expense for the nine months ended September 30, 2026 was $4.072 million, versus $7.411 million in the comparable prior-year period.

On the balance sheet, the filing reported total assets of $593.518 million and total equity of $284.090 million as of September 30, 2026. Total Core Laboratories Inc. shareholders' equity was $277.971 million, up from $265.986 million at December 31, 2025. Treasury stock stood at a cost of $15.453 million, reflecting 1,158,772 shares held, compared to $11.585 million for 871,489 shares at year-end 2025. Cash and cash equivalents were $21.376 million as of September 30, 2026, versus $22.702 million at December 31, 2025.

What Was Disclosed

Core Laboratories Inc. disclosed unaudited consolidated financial statements for the quarter and nine months ended September 30, 2026, covering revenue, operating income, net income, earnings per share, and balance sheet positions, as part of its quarterly report on Form 10-Q.